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Increased homocysteine (Hcy) level has been implicated as an independent risk factor for various neu-
rological disorders, including Parkinson’s disease (PD). Hcy has been reported to cause dopaminergic
neuronal loss in rodents and causes the behavioral abnormalities. This study is an attempt to investigate
molecular mechanisms underlying Hcy-induced dopaminergic neurotoxicity after its chronic systemic
administration. Male Swiss albino mice were injected with different doses of Hcy (100 and 250 mg/kg;
intraperitoneal) for 60 days. Animals subjected to higher doses of Hcy, but not the lower dose, produces
motor behavioral abnormalities with signiﬁcant dopamine depletion in the striatum. Signiﬁcant in-
hibition of mitochondrial complex-I activity in nigra with enhanced activity of antioxidant enzymes in
the nigrostriatum have highlighted the involvement of Hcy-induced oxidative stress. While, chronic
exposure to Hcy neither signiﬁcantly alters the nigrostriatal glutathione level nor it causes any visible
change in tyrosine hydroxylase-immunoreactivity of dopaminergic neurons. The ﬁnding set us to hy-
pothesize that the mild oxidative stress due to prolonged Hcy exposure to mice is conducive to striatal
dopamine depletion leading to behavioral abnormalities similar to that observed in PD.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Homocysteine (Hcy) - a non-proteogenic sulphur containing
amino acid, is known to increase in plasma of Parkinson’s disease
(PD) patients under treatment with the gold standard drug, L-
DOPA (L-3,4-dihydroxyphenylalanine) [1–4]. The methylation of L-
DOPA by catechol-O-methyl transferase is the leading cause of
elevated level of plasma Hcy in PD patients [5,6]. Several in vitro
studies have highlighted the neurotoxic potency of Hcy to various
neuronal types, including dopaminergic neurons [7–10]. The toxic
potency of Hcy to dopaminergic neurons is also reported from
animal models of PD [8,10–12]. Intraperitoneal injection of Hcy at
a high dose (500 mg/kg) for a long time (36 days) caused a re-
duction of tyrosine hydroxylase (TH)-positive neurons, while do-
pamine and its metabolite remained unchanged [13]. Chandra
et al. [11] have shown for the ﬁrst time the direct effect of Hcy on
dopaminergic neurons by intranigral administration of Hcy.an open access article under the CUnilateral, intranigral injection of Hcy caused a signiﬁcant de-
crease in striatal dopamine levels and loss of striatal dopaminergic
neurons [11]. However, the underlying mechanism of Hcy-induced
neurotoxicity to nigrostriatal dopaminergic neurons remains un-
explained. However, Hcy-induces excitotoxicity, oxidative stress
and mitochondrial alterations in cellular neuronal model leading
to apoptosis and neuronal cell death [14–16]. Also, Hcy itself can
serve as a pro-oxidant that contributes to oxidative stress in
neuronal cells [17]. Hoffman [18] suggested that Hcy is a putative
marker of cellular oxidant status.
Although the exact molecular mechanism of death of midbrain
dopamine containing neurons in PD is not known clearly, however,
oxidative stress has been postulated as the foremost event in PD
pathogenesis [19]. Human postmortem studies indicated down
regulation of antioxidant protective mechanisms in PD brain
[20,21]. The present study examined the involvement of oxidative
stress mechanisms in Hcy-induced dopaminergic neurotoxicity in
mice. The effect of prolonged (60 days) systemic administration of
Hcy on motor behavior, striatal dopamine levels and nigrostriatal
enzymatic (SOD, superoxide dismutase and catalase) as well as
non-enzymatic (reduced glutathione) oxidative stress parameters
were investigated in mice. We also investigated the status ofC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in mice. The ﬁndings may have important implications for un-
derstanding the pathogenesis of PD.Fig. 1. Effect of chronic Hcy administration on (A) Akinesia and (B) Catalepsy.
Akinesia and catalepsy were measured after daily administration of Hcy (100 mg/
kg or 250 mg/kg) or vehicle on 14th, 28th, 42nd and 56th day. The effect of Hcy
administration on the latency to move all four limbs (akinesia) as compared to the
control group were examined (measured in sec). The effects of Hcy administration
to correct an externally imposed posture (catalepsy) as compared to the control
group were examined (measured in sec). The data represented are mean7SEM.
*Pr0.05 as compared to control (n¼6).2. Materials and methods
2.1. Animals
Eight-weeks-old male Swiss albino mice (23–26 g) were used
in the present study. The animals were maintained under standard
conditions of 12 h light/dark cycles, 2472 °C temperatures and
6075% humidity. They were provided with food and water ad
libitum. The experimental protocols met the National Guidelines
and were approved by the Animal Ethics Committee of the
University.
2.2. Materials
D,L-homocysteine (Sigma-Aldrich Cat# H4628), reduced glu-
tathione (GSH), hydrogen peroxide (H2O2), ortho-phthalaldehyde,
phosphoric acid (H3PO4), Triton X-100, bovine serum albumin
(BSA), and ethylenediaminetetraacetic acid disodium salt (EDTA)
were purchased from Sigma-Aldrich Co (St. Louis, MO, USA).
Rabbit anti-tyrosine hydroxylase (TH) primary antibody and anti-
rabbit goat secondary antibody were purchased from Millipore Co.
(USA). Pyrogallol and other reagents were procured from Sisco
Research Laboratories Pvt. Ltd. Maharashtra, India.
2.3. Experimental design
Two groups of mice containing 6 animals were treated with
Hcy (100 or 250 mg/kg daily, i.p.) dissolved in vehicle (0.9% So-
dium Chloride) daily for 60 days and another group received the
vehicle. The volume of Hcy and vehicle injected as per body
weight of the animals. In the lower dose group, Hcy was given
once a day at a dose 100 mg/kg (74 mM). In the highest dose
group, Hcy was given twice a day at a dose 125 mg/kg (92 mM), so
cumulative dose was 250 mg/kg per day. Motor behavioral tests
(akinesia and catalepsy) were conducted on 14th, 28th, 42nd and
56th day and swim test on the 56th day of daily Hcy or vehicle
administration. After the last dose of Hcy or vehicle administra-
tion, animals were sacriﬁced for analysis of striatal dopamine,
oxidative stress parameters and mitochondrial complex activity
from substantia nigra (SN) and striatum (NCP). Animals that re-
ceived Hcy alone or vehicle for 60 days were perfused for TH-
immunohistochemistry of SN and NCP. Each assay was repeated at
least twice on separate days.
2.4. Behavioral test
2.4.1. Akinesia
Akinesia was measured by noting the latency of animals in
seconds (s) to move all the fore and hind limbs on an elevated
wooden platform (40 cm40 cm30 cm). The test terminated if
the animal remains latent upto 180 s [22].
2.4.2. Catalepsy
Catalepsy can be deﬁned as the inability of an animal to correct
an externally imposed posture. Animals were placed on a ﬂat
horizontal surface with both hind limbs placed on a 3 cm high
square wooden block and the time period (in seconds) that the
animal took to move from the block to horizontal surface was
noted down [22].2.4.3. Swim test
Swimming ability test [23] was carried out in tubs with 40 cm
length, 25 cm width and 16 cm height. The level of water was
maintained upto 12 cm at 27–28 °C. Animals were placed in water
and the swimming ability was scored every min for a period of
10 min. The scoring scale is as follows: 3-continuous swimming,
2-swimming with occasional ﬂoating, 1-more ﬂoating with occa-
sional swimming with hind limbs and 0-hind part sinks with only
the head ﬂoating. Total swim score is the sum of scores obtained in
each minute for the entire test period of 10 min.
2.5. Dopamine analysis
Striatum was dissected out from Hcy or vehicle treated animals
after 60 daily injections and fresh 50 μl (1 μg/μl) striatal lysates (in
STEN buffer) were detected with 50 μl primary antibody (1 h) and
100 μl anti-rabbit secondary antibody (30 min) at room tempera-
ture according to the manufacturer’s protocols (Abnova, Taiwan)
for dopamine [24].
2.6. Estimation of brain Hcy levels
For brain Hcy estimation, the animals were killed at 2 h after
the last dose of Hcy or vehicle on 60th day of treatment. The right
and left NCP were dissected out, whereas the right and left SN
were micropunched from 1 mm frozen brain sections. The right
and left hemisphere were processed together for Hcy estimation.
The tissues were weighed and sonicated in PBS and stored over-
night. After two freeze–thaw cycles, the homogenates were cen-
trifuged at 5000 g for 5 min and the supernatant was analyzed for
Hcy content. The total Hcy content was analyzed in brain homo-
genates using the Hcy ELISA kit (KA1242; Abnova, Taiwan) as per
the manufacturer’s protocol.
2.7. Mitochondrial complex-I activity
Complex-I activity was assayed as described earlier [25]. Mice
were sacriﬁced after the last dose of Hcy or vehicle and complex-I
Fig. 2. Effect of chronic Hcy administration on swimming ability. Swim test was performed after daily administration of Hcy (100 mg/kg or 250 mg/kg) or vehicle on 56th
day. Animals were placed in water and the swimming ability was scored every min for a period of 10 min (2A). Total swim score (2B) signiﬁcantly reduced in animals those
received highest dose of Hcy. The data represented are mean7SEM. *Pr0.05 as compared to control (n¼6).
Fig. 3. Effect of chronic Hcy administration on striatal dopamine (DA) level. Mice
were administered Hcy (100 mg/kg or 250 mg/kg i.p) or vehicle for 60 days and
were sacriﬁced. Striatal DA level was analyzed by using ELISA kit. Results are ex-
pressed as mean7SEM. *Pr0.05 as compared to control (n¼6).
Fig. 4. Effect of chronic Hcy administration on complex-I activity. Mice were
treated with Hcy (100 mg/kg or 250 mg/kg) or vehicle daily were sacriﬁced on 60th
day after the last dose and complex-I activity was measured in the (A) nucleus
caudatus putamen (NCP) and (B) substantia nigra (SN) region by employing a
spectrophotometric procedure using NADH as substrate. Results given are
mean7SEM of nmol of NADH oxidized/min/mg protein. *Pr0.05 as compared to
control (n¼6).
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punctured SN and NCP from fresh frozen sections were sonicated
in 0.1 M potassium phosphate buffer, pH 7.8, centrifuge at 600 g
for 20 s and complex-I activity as assessed from the supernatant.
The assay was carried out in the presence and absence of 5 μmol/L
rotenone in order to derive the rotenone sensitive complex-I ac-
tivity. The speciﬁc enzyme activity is expressed as nmol NADH
oxidized/min/mg protein (e340¼6.23103 M).
2.8. Estimation of reduced glutathione levels
The reduced glutathione (GSH) content in SN and NCP of mice
treated with Hcy or vehicle was estimated after last dose of
treatment by employing ortho-phthalaldehyde condensation re-
action following the method described earlier [26,27]. The mi-
cropunched tissues were homogenized separately in 0.1 M po-
tassium phosphate buffer, pH 7.8. After centrifugation the cytosolic
fractions were deprotonated with ice-cold 0.1 M H3PO4 (10%, v/v).
The supernatant treated with o-pthaldialdehyde (0.1%) and in-
cubated for 20 min at room temperature, which yield a ﬂuorescent
product due to ortho-phthalaldehyde condensation reaction
with GSH. Readings of the ﬂuorescent product were taken atactivation/emission wavelengths of 337/423 nm. A standard curve
was prepared by using commercially obtained GSH and results
were expressed as nanograms per milligram fresh tissue.
2.9. Determination of SOD activity
Mice treated with Hcy or vehicle were sacriﬁced at the end of
60th day of treatment period following last dose of Hcy. SOD ac-
tivity was analyzed in the cytosolic fractions of NCP and SN by
employing the method of Marklund and Marklund [28]. The assay
mixture (3 ml) contained 0.2 mM of pyrogallol, 1 mM of EDTA and
50 mM of Tris–HCl buffer, pH 8.2. Auto oxidation of pyrogallol was
measured spectrophotometrically at 420 nm for 3 min with or
Fig. 5. Effect of chronic Hcy administration on nigrostriatal GSH. Mice were treated
with Hcy (100 mg/kg or 250 mg/kg) or vehicle daily for 60 days. Animals were
sacriﬁced after the last dose of Hcy or vehicle administration and GSH was mea-
sured in the (A) nucleus caudatus putamen (NCP) and (B) substantia nigra (SN)
region by employing a sensitive spectroﬂuorimetric procedure. Results given are
mean7SEM in ng/mg tissue. *Pr0.05 as compared to control (n¼6).
Fig. 6. Effect of chronic Hcy administration on superoxide dismutase (SOD) activity.
Mice were sacriﬁced after 60 daily administration of Hcy (100 mg/kg or 250 mg/kg)
or vehicle. SOD activity measured from the cytosolic fraction of (A) nucleus cau-
datus putamen (NCP) and (B) substantia nigra (SN) region by employing pyrogallol
oxidation method. Results given are mean7SEM. *Pr0.05 as compared to control
(n¼6).
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linear with the activity of the enzyme present. Fifty percent in-
hibition in pyrogallol auto oxidation/mg protein/min is taken as
one unit of the enzyme activity.
2.10. Determination of catalase activity
Catalase activity was assayed based on the method of Aebi H
[29]. Mice treated with Hcy or vehicle for 60 days were sacriﬁced
after the last dose and catalase activity was analyzed in the cyto-
solic fractions of NCP and SN. An assay mixture of 500 mL con-
tained suitably diluted enzyme protein (75–100 mg), in 50 mM of
phosphate buffer, pH 7.0. The reaction was started by the addition
of hydrogen peroxide (30 mM) and decomposition of hydrogen
peroxide was measured at 240 nm for 30 s in presence of the
enzyme in spectrophotometer. The speciﬁc activity is represented
as change in absorbance/min/mg protein.
2.11. TH-immunohistochemistry
The Hcy or vehicle treated mice were anesthetized with chloral
hydrate (350 mg/kg; i.p.) and perfused intracardially with phos-
phate buffer saline (PBS, pH 7.4) followed by 4% para-for-
maldehyde. Brains were removed and kept in 4% para-for-
maldehyde, transferred to 30% sucrose and coronal sections
(20 mm thickness) passing through SN or NCP was taken by using
Cryotome (0620E Cryostat, Thermo Shandon, United Kingdom).
The sections were rinsed three times with 0.1 M PBS (pH 7.4),
incubated in 1% H2O2 in PBS, permeabilized with 0.4% Triton
X-100, blocked with 8% BSA containing 0.1% Triton X-100. Thesections were incubated with the primary antibody (1:100) in PBS,
containing 4% BSA for overnight at 4 °C and then incubated with
secondary anti-rabbit IgG-conjugated horseradish peroxidase an-
tibody (1:500) in PBS containing 2% BSA for 1 h at room tem-
perature. Visualization was performed by incubation in 3, 3-dia-
minobenzidine for 5 min and the sections were photographed by
using a Trinocular microscope (Eclipse, Ci, Nikon, Japan).
2.12. Statistics
Statistical analysis was performed using the SigmaStat version
3.5 software. The data were analyzed employing Student’s t-test.
Results are given as mean7S.E.M. Values of pr0.05 were con-
sidered signiﬁcant.3. Results
3.1. Effect of chronic Hcy administration on motor behaviors
3.1.1. Akinesia
The animals that received the higher doses of Hcy (250 mg/kg)
were signiﬁcantly akinetic as compared to control (Fig. 1A) when
examined on 56th day, but not at other time points used (Fig. 1A).
Fig. 7. Effect of chronic Hcy administration on catalase (CAT) activity. Mice were
sacriﬁced after 60 daily administration of Hcy (100 mg/kg or 250 mg/kg) or vehicle.
CAT activity measured from the cytosolic fraction of (A) nucleus caudatus putamen
(NCP) and (B) substantia nigra (SN) region. Results given are mean7SEM in pmol/
mg tissue. *Pr0.05 as compared to control (n¼6).
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deﬁcits at any time points in any animals examined (Fig. 1A).
3.1.2. Catalepsy
Chronic administration of Hcy (250 mg/kg; i.p., daily) caused
signiﬁcant cataleptic deﬁcits in animals when examined on 42nd
and 56th day of Hcy administration (Fig. 1B). The lower dose of
Hcy produces the deﬁcits on 56th day, when compared to control
(Fig. 1B). Hcy administration did not show any effect on catalepsy
on other time points examined.
3.1.3. Swim test
In swim ability test, where general motor activity is revealed,
animals treated with higher dose of Hcy (250 mg/kg) displayed
signiﬁcantly poorer swimming ability on 56th day as compared to
the control (Fig. 2A). However, the lower dose of Hcy (100 mg/kg)
did not show any effect on the swimming ability when examined
on 56th day (Fig. 3A). The swim scores at the 1st min was 2.8 and
2.7 for control and Hcy (250 mg/kg) group, whereas from 2nd min
to 10th min there were progressive decrease in swimming score of
Hcy (250 mg/kg) group compared to control group and at the 10th
min score was 2.1 and 1.14 for control and Hcy (250 mg/kg) group
respectively. Also, total swims score observed in the test period of
10 min of animals that received highest dose of Hcy signiﬁcantlylesser which is 19.6 as compared to the vehicle treated animals
(24.41) (Fig. 2B).
3.2. Effect of chronic Hcy administration on striatal dopamine levels
A signiﬁcant decrease in striatal dopamine level was observed in
animals treated with higher dose of Hcy (250 mg/kg) but not with
the lower dose (100 mg/kg) after the 60th day of treatment (Fig. 3).
The striatal dopamine level was decreased by 11% and 21% re-
spectively in animals treated with lower and higher doses of Hcy.
3.3. Effect of chronic Hcy administration on nigrostriatal Hcy levels
A signiﬁcant increase in the nigrostriatal Hcy level was ob-
served in animals treated with higher dose of Hcy (250 mg/kg; i.p.,
daily) but not with the lower dose (100 mg/kg; i.p., daily) as
compared to vehicle treated group. The value of Hcy in NCP and SN
in vehicle treated group was 0.4670.06 and 0.4970.05 pmol/mg
tissue, while in Hcy (250 mg/kg) treated group was 0.770.07 and
0.7570.06 pmol/mg tissue respectively.
3.4. Effect of chronic Hcy administration on complex-I activity
Mitochondrial complex-I activity was signiﬁcantly inhibited by
20% in the SN of animals treated with higher dose of Hcy (250 mg/
kg) but not with the lower dose (6%), as compared to control
(Fig. 4B). However, in NCP the mitochondrial complex-I activity
was inhibited by 4% and 5.5% by lower and higher doses of Hcy
respectively as compared to control, which is not statistically sig-
niﬁcant (Fig. 4A).
3.5. Effect of chronic Hcy administration on glutathione level
Daily treatment of Hcy (100 mg/kg and 250 mg/kg) caused no
signiﬁcant differences in the SN or striatal GSH contents, when
compared with vehicle treated animals (Fig. 5).
3.6. Effect of chronic Hcy administration on SOD activity
The brain antioxidant enzyme, superoxide dismutase (SOD)
activity in the SN and NCP of mice treated with Hcy for 60 days
was signiﬁcantly increased as compared to vehicle treated mice
(Fig. 6). In NCP and SN, higher dose of Hcy (250 mg/kg) sig-
niﬁcantly increases SOD activity by 81% and 25% respectively as
compared to control. While the lower dose of Hcy (100 mg/kg)
increases SOD activity in NCP by 30% and in SN by 7%, which are
not signiﬁcant statistically as compared to control.
3.7. Effect of chronic Hcy administration on catalase activity
Catalase activity in the SN and NCP of mice treated with Hcy for
60 days was increased signiﬁcantly as compared to vehicle treated
mice (Fig. 7). In NCP and SN, higher dose of Hcy (250 mg/kg) sig-
niﬁcantly increases catalase activity by 31% and 57% respectively,
as compared to control. The lower dose of Hcy (100 mg/kg) in-
creased the catalase activity in SN by 29% and by 18% in NCP,
which are not signiﬁcant statistically as compared to control.
3.8. Effect of chronic exposure of Hcy on TH-immunoreactivity in SN
and NCP of mice
Positive staining for TH was obtained as dark brown colour in
the NCP and SN of mice that received vehicle for 60 days (Fig. 8A,
C). No visible changes in the TH-immunoreactivity in NCP (Fig. 8B)
as well as in SN (Fig. 8D) were observed on 60th day following
daily Hcy (250 mg/kg) treatment, when compared to control.
Fig. 8. Tyrosine hydroxylase-immunoreactivity (TH-IR) of dopaminergic neurons. Mice injected with Hcy (250 mg/kg; i.p.) or vehicle daily for 60 days were sacriﬁced after
the last dose and perfused transcardially. Cryocut coronal sections (20 mm) passing through the striatum (A, B) and substantia nigra (C, D) were processed for TH-IR. (A) and
(C) are sections from vehicle treated animals; (B) and (D) are sections from Hcy treated (250 mg/kg, i.p.) animals. No visible changes in TH-IR were observable in the neurons
from treated sections.
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The present study demonstrates the involvement of oxidative
stress mechanism in Hcy-induced dopaminergic neurotoxicity. The
major ﬁndings come out of the present study that prolonged in-
traperitoneal administration of Hcy in mice leads to (i) motor
behavioral deﬁcits similar to PD (ii) depletion of dopamine in the
striatum (iii) decrease in nigral mitochondrial complex-I activity
and oxidative stress by modulating the levels of antioxidant en-
zymes in nigrostriatal regions.
One of most important ﬁnding of the present study is the loss
of signiﬁcant motor activity in Hcy exposed animals which is si-
milar to that found in experimental models of PD. The display of
increased latency in akinesia and catalepsy (Fig. 1) and decrease in
swimming ability (Fig. 2) are the indications of reduced motor
activity. Hcy infusion directly into the SN reported to exacerbate
motor dysfunction in animal models of PD as evidenced from
Rotarod test [8] and drug-induced rotational bias [12]. Intranigral
infusion of Hcy caused dopaminergic drug-induced stereotypic
rotational bias in rats [11]. When injected intraperitoneal route for
60 days, Hcy (50 mg/kg and 100 mg/kg) caused a signiﬁcant de-
crease in locomotor activities in mice [13]. However, our result
that chronic systemic exposure to Hcy decreased motor activity
signiﬁcantly by increasing latency in akinesia, catalepsy and de-
creasing swimming score is the ﬁrst report of such. It has been
demonstrated that motor deﬁcits are correlated to depleted levels
of striatal dopamine in experimental models of PD [30,31]. Ani-
mals were sacriﬁced for striatal dopamine analysis and we ob-
served a 21% decrease in striatal dopamine in animals that re-
ceived higher dose of Hcy (250 mg/kg) (Fig. 3). Therefore, our data
clearly demonstrate that higher concentration of Hcy administra-
tion at a long-time is detrimental to the motor abilities of animals,
which could be due to signiﬁcant striatal dopamine depletion
(Fig. 3).
In the present study, prolonged Hcy exposure to mice inhibits
nigral complex-I activity, which is an important and interesting
ﬁnding (Fig. 4). Defects in mitochondrial complexes activity,particularly complex-I have been found in PD brain [32,33] as well
as in toxins-induced animal models of PD [34,35]. Long-term Hcy
treatment induced inhibition of complex-I activity could be re-
sulting from the enhanced production of free radicals in the nigra
[22], which in turn contributes to oxidative stress [36]. Yet another
important observation of the present study is the signiﬁcant in-
crease in activity of antioxidant enzymes, SOD and catalase in
nigrostriatum of mice by chronic intraperitoneal administration of
Hcy (Figs. 6 and 7). The parkinsonian neurotoxins-induced oxi-
dative stress in nigral neurons also reported to elevate the activity
of SOD and catalase [25,37,38]. Dopaminergic neurons are parti-
cularly vulnerable to oxidative stress due to the presence of low
level of antioxidant defense system, including antioxidant en-
zymes [39].
GSH, a major cellular antioxidant defense system of brain, has
been reported to be decreased in nigra of PD brain [40]. The di-
minished level of GSH is regarded as the pioneer of all the dele-
terious events involved in dopaminergic neurodegeneration
[41,42]. However, in the present study, we did not ﬁnd a sig-
niﬁcant difference in the level of GSH in the nigrostriatum as a
result of chronic Hcy exposure to mice (Fig. 5). Also, we could not
ﬁnd a marked visible change in TH-immunoreactivity in SN as well
as NCP after prolonged intraperitoneal administration of Hcy
(Fig. 8). Whereas, Chandra et al. [11] have shown previously Hcy-
induced speciﬁc nigral neuronal loss and striatal dopamine de-
pletion (50%) only after intranigral infusion of Hcy. In animal
models of PD, intranigral infusion of Hcy exaggerates TH-positive
neuronal loss, however, Hcy alone did not produce any effect
[8,12]. Thus, our result that the chronic systemic administration of
Hcy caused mild oxidative stress in nigrostriatum, which is not
sufﬁcient to cause a signiﬁcant dopaminergic neuronal loss.5. Conclusion
The result indicates that Hcy has the ability to generate oxi-
dative stress in nigrostriatum, which may cause conditions
N. Bhattacharjee et al. / Biochemistry and Biophysics Reports 6 (2016) 47–53 53conducive to striatal dopamine depletion leading to behavioral
abnormalities. Also, L-DOPA treatment is known to increase Hcy
levels in plasma as well as in cerebro spinal ﬂuid of PD patients
[2,4]. Thus, it can be concluded that elevated level of this molecule
in parkinsonian patients may contribute to the progression of the
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